AB0483 CAN WE PREDICT WHICH PATIENTS WITH SPONDYLOARTHRITIS WILL NEED DOSE ESCALATION OF SECUKINUMAB TO 300 mg MONTHLY?
Diogo Fonsêca(Centro Hospitalar de Vila Nova de Gaia), Lúcia Costa(Hospital de São João), Miguel Bernardes(Hospital de São João), S. Garcia(Hospital de São João), F. R. Martins(Algarve Biomedical Center), F. Oliveira Pinheiro(Universidade do Porto), M. Rato(Universidade do Porto), D. Santos Oliveira, A. Martins(Hospital de São João), Bruno Miguel Fernandes(Hospital de São João)
Cited by 1
Related Papers
Oculomotor nerve palsy, an unusual onset of polyarteritis nodosa
|Reumatologia/Rheumatology|2023|5
SAT0465 FRACTURE RISK ASSESSMENT BY FRAX IN A SYSTEMIC LUPUS ERYTHEMATOSUS PORTUGUESE COHORT
|Annals of the Rheumatic Diseases|2020|4
Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
|International Journal of Environmental Research and Public Health|2023|3
SAT0449 SPONDYLOARTHRITIS AND FRACTURE RISK: DOES DXA REALLY HAVE AN IMPACT IN THE RISK OF FRACTURE ESTIMATED BY FRAX?
|Annals of the Rheumatic Diseases|2020|2